Non-Alginate Hydrogel Microparticles With Tunable Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional alginate microspheres suffer from poor biocompatibility and slow gelation rates, making them unsuitable for effective cell microencapsulation, while advanced hydrogels face challenges in non-emulsion-based fabrication and cytotoxicity.
Innovation Solution
Development of non-alginate hydrogel microparticles with covalently crosslinked polymer compounds, such as hyaluronic acid and polyethylene glycol, for encapsulating therapeutic cells, which are biocompatible and have tunable degradation profiles, allowing for localized delivery and sustained release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If traditional alginate microspheres are used for cell microencapsulation, then fabrication is simple and fast, but biocompatibility is poor
Solution Approach 1:
The patent changes the chemical composition parameters of the hydrogel matrix by using non-alginate polymers such as hyaluronic acid, polyethylene glycol, and gelatin instead of traditional alginate. This parameter change maintains ease of fabrication while significantly improving biocompatibility, as these alternative materials are known to be more biocompatible and support better cell survival and function.
Solution Approach 2:
The patent employs composite hydrogel materials that combine multiple polymer components (e.g., hyaluronic acid with polyethylene glycol, or gelatin with other biocompatible polymers). These composite materials leverage the advantages of each component to achieve both ease of manufacture and high biocompatibility, resolving the contradiction between fabrication simplicity and biological compatibility.
2Object-affected harmful factors
If advanced hydrogels are used for cell microencapsulation, then biocompatibility improves, but gelation rate becomes slow
Solution Approach 1:
The patent incorporates pre-functionalized polymer precursors that are prepared in advance with reactive groups ready for crosslinking. This preliminary action allows the hydrogel to gelate rapidly when exposed to crosslinking agents or environmental triggers, eliminating the slow gelation problem while maintaining the high biocompatibility of advanced hydrogel materials.
Solution Approach 2:
The patent utilizes phase transition mechanisms (such as temperature-induced gelation or pH-triggered crosslinking) to enable rapid gelation of biocompatible hydrogels. By designing the hydrogel system to undergo controlled phase transitions under specific conditions, the patent achieves fast gelation rates while preserving the excellent biocompatibility of advanced hydrogel materials.
3Object-affected harmful factors
If non-alginate hydrogel microparticles are developed, then biocompatibility and tunable degradation are achieved, but fabrication complexity increases
Solution Approach 1:
The patent segments the fabrication process into distinct, modular stages: polymer precursor preparation, crosslinking agent addition, microparticle formation, and degradation control. Each stage can be independently optimized and controlled, making the overall complex fabrication process more manageable and reproducible while achieving high biocompatibility and tunable degradation.
Solution Approach 2:
The patent systematically controls fabrication parameters (polymer concentration, crosslinker ratio, molecular weight, functional group density) to tune the properties of non-alginate hydrogel microparticles. By establishing clear parameter relationships, the patent makes the fabrication of complex biocompatible materials more predictable and less complex.
4Speed
If degradation rate is increased for faster release, then therapeutic delivery speed improves, but cell protection duration decreases
Solution Approach 1:
The patent creates dynamically adjustable degradation systems where the degradation rate can be tuned to match specific therapeutic requirements. By incorporating crosslinkers with different bond strengths and hydrolysis rates, the patent enables the hydrogel matrix to degrade at controlled speeds, allowing optimization between fast therapeutic delivery and extended cell protection based on the specific application needs.
Solution Approach 2:
The patent changes the chemical parameters of the crosslinking system (crosslinker type, concentration, molecular weight) to precisely control the degradation rate. This parameter control allows the patent to optimize the balance between degradation speed for therapeutic release and duration for cell protection, resolving the contradiction between these two opposing requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microparticles maintain high cell viability (>50%) and controlled release of therapeutic agents over several hours to months, protecting cells from degradation and immune response, with customizable degradation rates and minimal cytotoxicity.
Implementation Method 1
a 3-dimensional matrix of covalently crosslinked non-alginate polymer compounds
Implementation Method 2
non-alginate hydrogel microparticles with covalently crosslinked polymer compounds
Implementation Method 3
customizable degradation rates
Data Source
AI summary
Non-alginate hydrogel microparticles for localized delivery and sustained release of therapeutic cells and/or tissues (including homogenous or heterogenous cell clusters) at a site of implantation. The microparticles comprise a 3-dimensional matrix of covalently crosslinked non-alginate polymer compounds and a therapeutically-effective amount of cells and/or tissue entrapped therein, wherein the cells have a viability of at least about 50%, and wherein the microparticle has a size of greater than about 30 pm. Compositions containing such microparticles and methods of using such microparticles for treatment are also described.